Recent News

• 10.27.2026 - Nexalin Technology Announces Fourth Peer-Reviewed Publication in Alzheimer’s Disease: 15 mA DIFS™ Significantly Improves Sleep Quality in Patients with Mild Alzheimer’s Disease
• 10.08.2026 - Nexalin Technology Regains Compliance with Nasdaq Minimum Bid Price Requirement; Nasdaq Hearings Panel Grants Request for Continued Listing
• 10.01.2026 - Nexalin Technology Signs Definitive Exclusive Distribution and Local Manufacturing Agreement for Brazil and South America, Marking a Major Step in its Transition Toward Commercial Revenue Generation
• 09.29.2026 - Nexalin Technology Taps Neuromodulation Commercial Executive Robert DiTota to Advise on its Global Commercialization Strategy
• 09.03.2026 - Nexalin Technology Announces New Secondary Analysis of Previously Published Clinical Trial Data Reveals Previously Unreported Improvements in Memory, Comprehension and Language Function in Alzheimer’s Patients; ADAS-Cog Subscale Analysis to Guide Design of Planned U.S. Alzheimer’s Pilot Study
• 08.27.2026 - Nexalin Technology Announces Reverse Stock Split
• 06.23.2026 - Nexalin Technology Announces that the Investigator of Its Brazilian Clinical Trial Received the Young Researcher Award at BRAIN 2026 for Research Evaluating the Company’s Proprietary DIFS™ Platform
• 06.16.2026 - Nexalin Technology Announces Two Clinical Abstracts Accepted for Presentation at the 2026 NYC Neuromodulation Conference Highlighting Preliminary Clinical Results Across Anxiety, Depression, Insomnia and Quality of Life
• 06.10.2026 - Nexalin Technology Reports Compelling Clinical Trial Results in Brazil to Support Product Launch. Trial Demonstrates 77.8% Anxiety Response Rate and Durable Benefits Across Depression, Insomnia and Quality of Life as Company Advances Brazilian Sales Plan.
• 06.04.2026 - Nexalin Technology Announces Issuance of U.S. Patent Covering Dynamic Frequency Stimulation for Anxiety, Depression and Insomnia

Recent Filings

• 10.27.2026 - PRE 14A Other preliminary proxy statements
• 10.15.2026 - EFFECT Notice of Effectiveness
• 10.08.2026 - S-1/A General form for registration of securities under the Securities Act of 1933
• 10.01.2026 - 8-K Current report
• 10.01.2026 - 8-K Current report
• 10.01.2026 - EX-99.1 EX-99.1
• 09.28.2026 - 8-K Current report
• 09.22.2026 - S-8 Securities to be offered to employees in employee benefit plans
• 09.03.2026 - S-1 General form for registration of securities under the Securities Act of 1933
• 09.03.2026 - SCHEDULE 13D General Statement of Acquisition of Beneficial Ownership